•  
  •  
 
Nano Research

Article Title

Efficient delivery of clay-based nanovaccines to the mouse spleen promotes potent anti-tumor immunity for both prevention and treatment of lymphoma

Authors

Ling-Xiao Zhang, Hwa Mei Hospital, University of Chinese Academy of Sciences , Ningbo 315010, China;Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia;State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China;School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, China
Ying-Bo Jia, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China;School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, China
Ya-Ru Huang, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China;School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, China
Hui-Na Liu, Hwa Mei Hospital, University of Chinese Academy of Sciences , Ningbo 315010, China;Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo 315010, China
Xia-Mei Sun, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
Ting Cai, Hwa Mei Hospital, University of Chinese Academy of Sciences , Ningbo 315010, China;Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo 315010, China
Rui-Tian Liu, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
Zhi Ping Xu, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia

Keywords

cancer immunotherapy, nanovaccine, layered double hydroxide, targeted delivery to the spleen, lymphoma

Abstract

Cancer therapeutic nanovaccines are ideal tools to inhibit tumor growth and provide the body with continuous protecting immune surveillance. However, the conventional subcutaneous (SC) vaccination normally induces limited anti-tumor immune responses with low therapeutic efficacy. Herein, we devised clay-based nanovaccines and directly delivered them to the spleen via intravenous (IV) injection to induce the stronger anti-tumor immunity with higher efficacy for tumor prevention and treatment. The clay, i.e., layered double hydroxide (LDH) was prepared as nanoadjuvant with the average size from 77 to 285 nm and co-loaded with the model antigen ovalbumin (OVA) and bioadjuvant CpG to form CpG/OVA-LDH (CO-LDH) nanovaccines. We found that CO-LDH-215 (the size of LDH was 215 nm) promoted dendritic cells to present the most antigen, and moreover showed the highest spleen enrichment (~ 1.67% of CO-LDH-215 enriched in the spleen at 24 h post IV injection). The in vivo immunologic data showed that CO-LDH-215 induced the most potent anti-tumor immune responses and completely prevented the growth of E.G7-OVA tumor in the mouse model. Furthermore, IV injected CO-LDH-215 nanovaccine more effectively delayed tumor growth than that SC injected, largely due to the direct and quick delivery of more nanovaccines to the spleen. This study demonstrates that the therapeutic efficacy of nanovaccines can be greatly enhanced by targeted delivery of nanovaccines to the spleen via the proper vaccination route.

Publisher

Tsinghua University Press

Share

COinS